Methyl 4-((3-(3-Pyridyloxy)propylsulfanyl)methyl)-tetrahydropyran-4-carboxylate | 235753-55-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl 4-((3-(3-Pyridyloxy)propylsulfanyl)methyl)-tetrahydropyran-4-carboxylate
• 英文别名: Methyl 4-(3-pyridin-3-yloxypropylsulfanylmethyl)oxane-4-carboxylate
• CAS: 235753-55-6
• 化学式: C₁₆H₂₃NO₄S
• 分子量: 325.429
• InChiKey: MPJUKBLRTHVJTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  83
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES
  申请人：——

  公开号：US20030236416A1

  公开（公告）日：2003-12-25

  Compounds having therapeutic utility are of formula (I) B—X—(CH 2 ) n —CR 2 R 3 —CR 4 R 5 —COY  (I) wherein n = 0 - 1; X is S(O) 0-2 , Y is OR 1 or NHOH; R 2 and R 4 are independently H or a group (optionally substituted with R 10 ) selected from C 1-6 alkyl, C 2-6 alkenyl, aryl, C 1-6 alkyl-aryl, heteroaryl, C 1-6 alkyl-heteroaryl, heterocycloalkyl, C 1-6 alkyl-heterocycloalkyl, cycloalkyl and C 1-6 alkyl-cycloalkyl; and R 1 , R 3 and R 5 are independently H or C 1-6 alkyl; provided that not more than two of R 2 , R 3 , R 4 and R 5 are H; or any of CR 2 R 3 , CR 4 R 5 and CR 2 —CR 4 is a cycloalkyl or heterocycloalkyl ring optionally substituted with R 10 or a group (optionally substituted with R 10 ) selected from C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl and C 1-6 alkyl-heteroaryl; B is heterocycloalkyl (optionally substituted by R 6 or R 7 ) bonded through carbon to X, or C 1-6 alkyl-heterocycloalkyl (optionally substituted with R 6 or R 7 ), or a group (substituted with R 6 ) selected from C 1-8 alkyl, C 2-6 alkenyl and C 2-6 alkynyl; R 6 is N(R 7 ) 2 , OR 7 , COR 7 , C(=NOR 9 )R 7 , NR 7 R 8 , S(O) 0-2 R 9 or SO 2 N(R 7 ) 2 ; R 7 is H or a group selected from C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl, C 1-6 alkyl-heteroaryl, cycloalkyl, C 1-6 alkyl-cycloalkyl, heterocycloalkyl and C 1-6 alkyl-heterocycloalkyl, wherein said group is optionally substituted with R 9 , COR 9 , SO 0-2 R 9 , CO 2 R 9 , OR 9 , CONR 1 R 9 , NR 1 R 9 , halogen, CN, SO 2 NR 1 R 9 or NO 2 , and for each case of N(R 7 ) 2 the R 7 groups are the same or different or N(R 7 ) 2 is heterocycloalkyl optionally substituted with R 9 , COR 9 , SO 0-2 R 9 , CO 2 R 9 , OR 9 , CONR 1 R 9 , NR 1 R 9 , halogen, CN, SO 2 NR 1 R 9 or NO 2 ; R 8 is COR 7 , CON(R 7 ) 2 , CO 2 R 9 or SO 2 R 9 ; R 9 is C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl or C 1-6 alkyl-heteroaryl; and R 10 is OR 7 , COR 7 , CO 2 R 1 , CON(R 7 ) 2 , NR 7 R 8 , S(O) 0-2 R 9 , SO 2 N(R 7 ) 2 , CN, halogen or cycloimidyl (optionally substituted with R 1 ); and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy and protected hydroxamic acid derivatives thereof.

  具有治疗效用的化合物的公式为(I)B—X—(CH2)n—CR2R3—CR4R5—COY  (I)，其中n为0-1；X为S(O)0-2，Y为OR1或NHOH；R2和R4独立地为H或从C1-6烷基、C2-6烯基、芳基、C1-6烷基芳基、杂芳基、C1-6烷基杂芳基、杂环烷基、C1-6烷基杂环烷基、环烷基和C1-6烷基环烷基中选择的（可选地用R10取代的）基团；R1、R3和R5独立地为H或C1-6烷基；但不得超过两个R2、R3、R4和R5为H；或CR2R3、CR4R5和CR2—CR4中的任何一个为杂环烷基或杂环烷基环，可选地用R10取代，或从C1-6烷基、芳基、C1-6烷基芳基、杂芳基和C1-6烷基杂芳基中选择的（可选地用R10取代的）基团；B为通过碳与X相连的杂环烷基（可选地用R6或R7取代），或C1-6烷基杂环烷基（可选地用R6或R7取代），或从C1-8烷基、C2-6烯基和C2-6炔基中选择的（用R6取代的）基团；R6为N(R7)2、OR7、COR7、C(=NOR9)R7、NR7R8、S(O)0-2R9或SO2N(R7)2；R7为H或从C1-6烷基、芳基、C1-6烷基芳基、杂芳基、C1-6烷基杂芳基、环烷基、C1-6烷基环烷基、杂环烷基和C1-6烷基杂环烷基中选择的基团，其中所述基团可选地用R9、COR9、SO0-2R9、CO2R9、OR9、CONR1R9、NR1R9、卤素、CN、SO2NR1R9或NO2取代，对于每种情况的N(R7)2，R7基团相同或不同，或N(R7)2为可选地用R9、COR9、SO0-2R9、CO2R9、OR9、CONR1R9、NR1R9、卤素、CN、SO2NR1R9或NO2取代的杂环烷基；R8为COR7、CON(R7)2、CO2R9或SO2R9；R9为C1-6烷基、芳基、C1-6烷基芳基、杂芳基或C1-6烷基杂芳基；R10为OR7、COR7、CO2R1、CON(R7)2、NR7R8、S(O)0-2R9、SO2N(R7)2、CN、卤素或环亚咪唑基（可选地用R1取代）；及其盐、溶剂化合物、水合物、N-氧化物、保护氨基、保护羧基和保护羟胺衍生物。
• Hydroxamic and carboxylic acid derivatives
  申请人：——

  公开号：US20040127717A1

  公开（公告）日：2004-07-01

  Compounds having therapeutic utility are of formula (I) B—X—(CH 2 ) n —CR 2 R 3 —CR 4 R 5 —COY  (I) wherein n=0-1; X is S(O) 0-2 ; Y is OR 1 or NHOH; R 2 and R 4 are independently H or a group (optionally substituted with R 10 ) selected from C 1-6 alkyl, C 2-6 alkenyl, aryl, C 1-6 , alkyl-aryl, heteroaryl, C 1-6 alkyl-heteroaryl, heterocycloalkyl, C 1-6 alkyl-heterocycloalkyl, cycloalkyl and C 1-6 alkyl-cycloalkyl; and R 1 , R 3 and R 5 are independently H or C 1-6 alkyl; provided that not more than two of R 2 , R 3 , R 4 and R 5 are H; or any of CR 2 R 3 , CR 4 R 5 and CR 2 -CR 4 is a cycloalkyl or heterocycloalkyl ring optionally substituted with R 10 or a group (optionally substituted with R 10 ) selected from C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl and C 1-6 alkyl-heteroaryl; B is heterocycloalkyl (optionally substituted by R 6 or R 7 ) bonded through carbon to X, or C 1-6 alkyl-heterocycloalkyl (optionally substituted with R 6 or R 7 ), or a group (substituted with R 6 ) selected from C 1-8 alkyl, C 2-6 alkenyl and C 2-6 alkynyl; R 6 is N(R 7 ) 2 , OR 7 , COR 7 , C(═NOR 19 )R 7 , NR 7 R 8 , S(O) 0-2 R 9 or SO 2 N(R 7 ) 2 ; R 7 is H or a group selected from C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl, C 1-6 alkyl-heteroaryl, cycloalkyl, C 1-6 alkyl-cycloalkyl, heterocycloalkyl and C 1-6 alkyl-heterocycloalkyl, wherein said group is optionally substituted with R 9 , COR 9 , SO 0-2 R 9 , CO 2 R 9 , OR 9 , CONR 1 R 9 , NR 1 R 9 , halogen, CN, SO 2 NR 1 R 9 or NO 2 , and for each case of N(R 7 ) 2 the R 7 groups are the same or different or N(R 7 ) 2 is heterocycloalkyl optionally substituted with R 9 , COR 9 , SO 0-2 R 9 , CO 2 R 9 , OR 9 , CONR 1 R 9 , NR 1 R 9 , halogen, CN, SO 2 NR 1 R 9 or NO 2 ; R 8 is COR 7 , CON(R 7 ) 2 , CO 2 R 9 or SO 2 R 9 ; R 9 is C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl or C 1-6 alkyl-heteroaryl; and R 10 is OR 7 , COR 8 , CO 2 R 1 , CON(R 7 ) 2 , NR 7 R 1 , S(O) 0-2 R 9 , SO 2 N(R 7 ) 2 , CN, halogen or cyclomidyl (optionally substituted with R 1 ); and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy and protected hydroxamic acid derivatives thereof.

  具有治疗作用的化合物为式(I) B-X-(CH 2 ) n -CR 2 R 3 -CR 4 R 5 -COY（I） 其中 n=0-1； X 是 S(O) 0-2 ; Y 是 OR 1 或 NHOH； R 2 和 R 4 独立地为 H 或一个基团（任选被 R 10 )选自 C 1-6 烷基、C 2-6 烯基、芳基、C 1-6 烷芳基、杂芳基、C 1-6 烷基杂芳基、杂环烷基、C 1-6 烷基异环烷基、环烷基和 C 1-6 烷基-环烷基；以及 R 1 , R 3 和 R 5 独立地为 H 或 C 1-6 烷基； 但 R 2 , R 3 , R 4 和 R 5 为 H；或 CR 2 R 3 、CR 4 R 5 和 CR 2 -CR 4 是环烷基或杂环烷基环，可选择被 R 10 或一个基团（任选被 R 10 ）选自 C 1-6 烷基、芳基、C 1-6 烷芳基、杂芳基和 C 1-6 烷基杂芳基； B 是杂环烷基（可选择被 R 6 或 R 7 )通过碳键与 X 或 C 1-6 烷基异环烷基（可选择被 R 6 或 R 7 )，或一个基团（被 R 6 ）或选自 C 1-8 烷基、C 2-6 烯基和 C 2-6 炔基； R 6 是 N(R 7 ) 2 ，OR 7 , COR 7 , C(═NOR 19 )R 7 ，NR 7 R 8 , S(O) 0-2 R 9 或 SO 2 N(R 7 ) 2 ; R 7 是 H 或选自 C 1-6 烷基、芳基、C 1-6 烷芳基、杂芳基、C 1-6 烷基杂芳基、环烷基、C 1-6 烷基环烷基、杂环烷基和 C 1-6 环烷基、C 1-6 烷基环烷基、杂环烷基和 C 1-6 烷基异环烷基，其中所述基团任选被 R 9 、COR 9 、SO 0-2 R 9 , CO 2 R 9 ，OR 9 , CONR 1 R 9 , NR 1 R 9 卤素、CN、SO 2 NR 1 R 9 或 NO 2 的每种情况下，N(R 7 ) 2 的 R 7 基团相同或不同，或 N(R 7 ) 2 是被 R 9 ，COR 9 、SO 0-2 R 9 , CO 2 R 9 ，OR 9 , CONR 1 R 9 , NR 1 R 9 卤素、CN、SO 2 NR 1 R 9 或 NO 2 ; R 8 是 COR 7 ，CON(R 7 ) 2 , CO 2 R 9 或 SO 2 R 9 ; R 9 是 C 1-6 烷基、芳基、C 1-6 烷芳基、杂芳基或 C 1-6 烷基杂芳基；以及 R 10 是 OR 7 ，COR 8 , CO 2 R 1 CON(R 7 ) 2 NR 7 R 1 , S(O) 0-2 R 9 , SO 2 N(R 7 ) 2 、CN、卤素或环甲酰基（可选择被 R 1 ); 及其盐类、溶液、水合物、N-氧化物、保护氨基、保护羧基和保护羟肟酸衍生物。
• US6680338B2
  申请人：——

  公开号：US6680338B2

  公开（公告）日：2004-01-20
• [EN] HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE ET CARBOXYLIQUE
  申请人：DARWIN DISCOVERY LIMITED

  公开号：WO1999040080A1

  公开（公告）日：1999-08-12

  (EN) Use of a compound for the manufacture of a medicament for the treatment or prevention of a condition associated with matrix metalloproteinases or that is mediated by TNF $g(a) or enzymes involved in the shedding of $i(L)-selectin, CD23, the TNF receptors, IL-1 receptors or IL-6 receptors, wherein the compound is of the formula (I): B-X-(CH2)n-CR2R3-CR4R5-COY.(FR) L'invention concerne l'utilisation d'un composé pour la fabrication d'un médicament se prêtant au traitement ou à la prévention d'un état qui est associé aux métalloprotéases de type matriciel ou bien dont la médiation est assurée par le TNF $g(a) ou par des enzymes intervenant dans la diffusion de la $i(L)-sélectine, du CD23 ainsi que des récepteurs du TNF et d'IL-1 ou d'IL-6. Ledit composé est représenté par la formule générale (I): B-X-(CH2)n-CR2R3-CR4R5-COY.